Herantis Pharma Plc, Company release, September 5, 2022 at 8:00 a.m. EEST
An aggregate number of 2,400 new shares of Herantis Pharma Plc (“Herantis“) have been subscribed for with option rights under the option program 2010. The new shares have been registered with the trade register maintained by the Finnish Patent and Registration Office today. The new shares will confer shareholder rights in Herantis after they have been issued in the book-entry system, on or about 2 September 2022.
Trading with the new shares is expected to commence on the Nasdaq First North Growth Market Finland marketplace on or about 6 September 2022, provided that Nasdaq Helsinki Ltd approves the listing application submitted by Herantis.
As a result of the share subscriptions, the total number of shares in Herantis will increase to 16,912,394.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel.: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
Herantis Pharma Plc
Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s Disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic version of the active parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the ability to be delivered to the brain via subcutaneous administration.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information, please visit https://www.herantis.com.